Modeling of oxidized PTH (oxPTH) and non-oxidized PTH (n-oxPTH) receptor binding and relationship of oxidized to non-oxidized PTH in children with chronic renal failure, adult patients on hemodialysis and kidney transplant recipients
- PMID: 23868100
- DOI: 10.1159/000350149
Modeling of oxidized PTH (oxPTH) and non-oxidized PTH (n-oxPTH) receptor binding and relationship of oxidized to non-oxidized PTH in children with chronic renal failure, adult patients on hemodialysis and kidney transplant recipients
Abstract
Background: The biological properties of oxidized and non-oxidized PTH are substantially different. Oxidized PTH (oxPTH) loses its PTH receptor-stimulating properties, whereas non-oxidized PTH (n-oxPTH) is a full agonist of the receptor. This was described in more than 20 well published studies in the 1970(s) and 80(s). However, PTH oxidation has been ignored during the development of PTH assays for clinical use so far. Even the nowadays used third generation assay systems do not consider oxidation of PTH We recently developed an assay to differentiate between oxPTH and n-oxPTH. In the current study we established normal values for this assay system. Furthermore, we compare the ratio of oxPTH to n-oxPTH in different population with chronic renal failure: 620 children with renal failure stage 2-4 of the 4C study, 342 adult patients on dialysis, and 602 kidney transplant recipients. In addition, we performed modeling of the interaction of either oxPTH or n-oxPTH with the PTH receptor using biophysical structure approaches.
Results: The children had the highest mean as well as maximum n-oxPTH concentrations as compared to adult patients (both patients on dialysis as well as kidney transplant recipients). The relationship between oxPTH and n-oxPTH of individual patients varied substantially in all three populations with renal impairment. The analysis of n-oxPTH in 89 healthy control subjects revealed that n-oxPTH concentrations in patient with renal failure were higher as compared to healthy adult controls (2.25-fold in children with renal failure, 1.53-fold in adult patients on dialysis, and 1.56-fold in kidney transplant recipients, respectively). Computer assisted biophysical structure modeling demonstrated, however, minor sterical- and/or electrostatic changes in oxPTH and n-oxPTH. This indicated that PTH oxidation may induce refolding of PTH and hence alters PTH-PTH receptor interaction via oxidation induced three-dimensional structure alteration of PTH.
Conclusion: A huge proportion of circulating PTH measured by current state-of-the-art assay systems is oxidized and thus not biologically active. The relationship between oxPTH and n-oxPTH of individual patients varied substantially. Non-oxidized PTH concentrations are 1.5 - 2.25 fold higher in patients with renal failure as compared to health controls. Measurements of n-oxPTH may reflect the hormone status more precise. The iPTH measures describes most likely oxidative stress in patients with renal failure rather than the PTH hormone status. This, however, needs to be demonstrated in further clinical studies. © 2013 S. Karger AG, Basel.
Similar articles
-
Unlocking the mysteries of n-oxPTH: implications for CKD patients.Front Endocrinol (Lausanne). 2025 Jan 3;15:1455783. doi: 10.3389/fendo.2024.1455783. eCollection 2024. Front Endocrinol (Lausanne). 2025. PMID: 39829956 Free PMC article. Review.
-
Nonoxidized, biologically active parathyroid hormone determines mortality in hemodialysis patients.J Clin Endocrinol Metab. 2013 Dec;98(12):4744-51. doi: 10.1210/jc.2013-2139. Epub 2013 Oct 30. J Clin Endocrinol Metab. 2013. PMID: 24171919
-
Non-oxidized PTH (n-oxPTH) is associated with graft loss in kidney transplant recipients.Clin Chim Acta. 2020 Sep;508:92-97. doi: 10.1016/j.cca.2020.05.022. Epub 2020 May 12. Clin Chim Acta. 2020. PMID: 32413401
-
Inverse correlation of intact PTH, oxidized PTH as well as non-oxidized PTH with 25-hydroxyvitamin D3 in kidney transplant recipients.Front Endocrinol (Lausanne). 2023 May 31;14:1178166. doi: 10.3389/fendo.2023.1178166. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37324252 Free PMC article.
-
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
Cited by
-
A case report of severe calciphylaxis - suggested approach for diagnosis and treatment.BMC Nephrol. 2017 Apr 21;18(1):137. doi: 10.1186/s12882-017-0556-z. BMC Nephrol. 2017. PMID: 28431568 Free PMC article.
-
Unlocking the mysteries of n-oxPTH: implications for CKD patients.Front Endocrinol (Lausanne). 2025 Jan 3;15:1455783. doi: 10.3389/fendo.2024.1455783. eCollection 2024. Front Endocrinol (Lausanne). 2025. PMID: 39829956 Free PMC article. Review.
-
Does PTH offer additive value to ALP measurement in assessing CKD-MBD?Perit Dial Int. 2014 Nov-Dec;34(7):687-91. doi: 10.3747/pdi.2014.00246. Perit Dial Int. 2014. PMID: 25520480 Free PMC article. Review. No abstract available.
-
Only bioactive forms of PTH (n-oxPTH and Met18(ox)-PTH) inhibit synthesis of sclerostin - evidence from in vitro and human studies.Pflugers Arch. 2024 Jun;476(6):889-899. doi: 10.1007/s00424-024-02928-x. Epub 2024 Feb 23. Pflugers Arch. 2024. PMID: 38393416 Free PMC article.
-
Sclerostin is an independent risk factor for all-cause mortality in kidney transplant recipients.Clin Exp Nephrol. 2020 Dec;24(12):1177-1183. doi: 10.1007/s10157-020-01956-y. Epub 2020 Aug 20. Clin Exp Nephrol. 2020. PMID: 32816133 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical